GLP-1 Analog Transdermal Patch

About QuiaPEG Pharmaceuticals

Quia Pharma AB, founded in 2008, is a Nasdaq First North-listed company that has undergone a radical strategic shift. Originally developing PEGylation technologies for drug delivery, it now operates a direct-to-consumer supplement business and is developing a transdermal GLP-1 patch for obesity. The company is in a state of significant distress, with its market maker agreement terminated and a clear intention to delist from the public market, casting severe doubt on its viability and strategic execution.

Therapeutic Areas

Other Obesity / Weight Management Drugs